
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc. has demonstrated a positive trajectory in its clinical development, notably reporting positive top-line results in June 2023 for its therapeutic candidates, which support their innovative approach to treating neurodegenerative diseases and psychiatric disorders. The company's unique offerings, AL001 and AL002, leverage patented technologies expected to enhance the efficacy of treatments for Alzheimer's, a critical area in need of effective solutions. Furthermore, the current valuation of Alzamend Neuro is considered attractive, with potential for significant upside based on a net present value analysis, suggesting that successful achievement of upcoming milestones could act as positive catalysts for the stock's performance.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly undershot estimates of $(0.69). The company's clinical-stage pipeline, while ambitious, faces substantial risks, including potential failures in demonstrating product safety and efficacy, regulatory approval challenges, and commercialization hurdles. Additional concerns stem from balance sheet and liquidity risks, heightened competition, and broader macroeconomic factors that could adversely affect investor sentiment towards biotechnology stocks.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares